PF07104091

CAS No. 2460249-19-6

PF07104091( PF-07104091 )

Catalog No. M28851 CAS No. 2460249-19-6

PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 491 Get Quote
5MG 780 Get Quote
10MG 1143 Get Quote
25MG 1701 Get Quote
50MG 2295 Get Quote
100MG 3087 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PF07104091
  • Note
    Research use only, not for human use.
  • Brief Description
    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
  • Description
    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PF-07104091
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2460249-19-6
  • Formula Weight
    404.46
  • Molecular Formula
    C19H28N6O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(=O)C1=CC(COC)=NN1C)C2=CC(=NN2)[C@@H]3C[C@H](OC(NC(C)C)=O)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yamaguchi T, et al. Determination of 7-chloro-3-(4-methyl-1-piperazinyl)-4h-1,2,4-benzothiadiazine-1,1-dioxide (DU-717) in plasma using electron-capture gas chromatography. J Chromatogr. 1978 Oct 11;160(1):181-90.
molnova catalog
related products
  • Compound 919278

    Compound 919278 is a specific inhibitor of lymphotoxin β receptor (LTβR, IC50=0.169 uM).

  • CDK9 inhibitor HH1

    CDK9 inhibitor HH1 is a novel potent, highly selective CDK9 inhibitor.

  • JNJ-7706621

    A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).